Aerie Pharmaceuticals Inc Revenue Growth Rates (AERI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Aerie Pharmaceuticals Inc   (NASDAQ: AERI)
 

AERI's Revenue Growth by Quarter and Year

Aerie Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AERI Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September 36.13
2nd Quarter June 33.31
1st Quarter March 29.84
FY 99.28





AERI Revenue third quarter 2022 Y/Y Growth Comment
Aerie Pharmaceuticals Inc reported Revenue improvement of 23.27% year on year in the third quarter 2022, to $ 36.13 millions, this is lower than Aerie Pharmaceuticals Inc 's recent average Revenue surge of 102.69%.

Looking into third quarter 2022 results within Biotechnology & Pharmaceuticals industry 28 other companies have achieved higher Revenue growth. While Aerie Pharmaceuticals Inc ' s Revenue rise of 23.27% ranks overall at the positon no. 1242 in the third quarter 2022.


AERI Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - 364.63 % 0.08 % 70.54 %
3rd Quarter September 23.27 % 45.97 % 8.31 % 153.97 %
2nd Quarter June 22.51 % 50.8 % 13.83 % 554.55 %
1st Quarter March 29.91 % 12.93 % 87.47 % -
FY   - 133.54 % 18.94 % -

Financial Statements
Aerie Pharmaceuticals Inc 's third quarter 2022 Revenue $ 36.13 millions AERI's Income Statement
Aerie Pharmaceuticals Inc 's third quarter 2021 Revenue $ 29.31 millions Quarterly AERI's Income Statement


AERI Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - 291.23 % 22.91 % 33.01 %
3rd Quarter September 8.46 % 7.8 % 11.37 % 17.05 %
2nd Quarter June 11.63 % 18.37 % -11.36 % 45.99 %
1st Quarter March -73.98 % -6.93 % -17.52 % -24.97 %
FY (Year on Year)   - 133.54 % 18.94 % -


Back to AERI Growth rate Comparisons >> Back to AERI Growth rate Comparisons >>


Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #29
Healthcare Sector #225
Overall #1242

Revenue Y/Y Growth Statistics
High Average Low
553.53 % 102.69 % 0.11 %
(Jun 30 2019)   (Dec 31 2020)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #29
Healthcare Sector #225
Overall #1242
Revenue Y/Y Growth Statistics
High Average Low
553.53 % 102.69 % 0.11 %
(Jun 30 2019)   (Dec 31 2020)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Aerie Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
291.18 % 37.2 % -73.98 %
(Dec 31 2021)  


AERI's III. Quarter Q/Q Revenue Comment
Aerie Pharmaceuticals Inc achieved in the III. Quarter 2022 below company average Revenue increase of 8.46% quarter on quarter, to $ 36.13 millions.

Although the III. Quarter 2022 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 7.8% growth in the III. Quarter a year ago

Within Biotechnology & Pharmaceuticals industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Aerie Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1328.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #37
Healthcare Sector #247
Overall #1328
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #37
Healthcare Sector #247
Overall #1328
Revenue Q/Q Growth Statistics
High Average Low
291.18 % 37.2 % -73.98 %
(Dec 31 2021)  


AERI's III. Quarter Q/Q Revenue Comment
Aerie Pharmaceuticals Inc achieved in the III. Quarter 2022 below company average Revenue increase of 8.46% quarter on quarter, to $ 36.13 millions.

III. Quarter 2022 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 7.8% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Aerie Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1328.


Aerie Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 213.94 $ 207.13 $ 201.00 $ 194.13 $ 104.15
Y / Y Revenue Growth (TTM) 105.41 % 118.21 % 134.35 % 133.51 % 25.31 %
Year on Year Revenue Growth Overall Ranking # 130 # 220 # 98 # 86 # 1142
Seqeuential Revenue Change (TTM) 3.29 % 3.05 % 3.54 % 86.4 % 9.73 %
Seq. Revenue Growth (TTM) Overall Ranking # 802 # 1540 # 865 # 56 # 902


Cumulative Revenue growth Comment
Assuming the Aerie Pharmaceuticals Inc 's fiscal year would have ended in Sep 30 2022, Aerie Pharmaceuticals Inc would have reprted above average annual Revenue surge of 105.41% year on year, of $ 214 millions.
This marks a slow-down of the companys growth trends and from the 118.21% surge in Jun 30 2022.

Within the Healthcare sector 28 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 130, from total ranking in previous quarter at 220.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 23
Healthcare Sector # 29
Overall # 130

Revenue TTM Y/Y Growth Statistics
High Average Low
134.35 %
 72.22 %
8.05 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 101
S&P 500 # 802
Cumulative Revenue growth Comment
Assuming the Aerie Pharmaceuticals Inc 's fiscal year would have ended in Sep 30 2022, Aerie Pharmaceuticals Inc would have reprted above average annual Revenue surge of 105.41% year on year, of $ 214 millions.
This marks a slow-down of the companys growth trends and from the 118.21% surge in Jun 30 2022.

Within the Healthcare sector 28 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 130, from total ranking in previous quarter at 220.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 23
Healthcare Sector # 29
Overall # 130

Revenue TTM Y/Y Growth Statistics
High Average Low
134.35 %
72.22 %
8.05 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 101
S&P 500 # 802




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AERI's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2022
Endonovo Therapeutics Inc 40.69%$ 40.693 millions
Oak Street Health Inc 40.39%$ 40.391 millions
Akoya Biosciences Inc 39.89%$ 39.893 millions
Kamada Ltd 39.87%$ 39.867 millions
Y mabs Therapeutics inc 39.84%$ 39.844 millions
Tscan Therapeutics Inc 39.43%$ 39.428 millions
Orthopediatrics Corp39.36%$ 39.360 millions
Xencor Inc38.69%$ 38.693 millions
Viewray Inc 38.13%$ 38.134 millions
23andme Holding Co37.05%$ 37.053 millions
Privia Health Group Inc 36.33%$ 36.329 millions
Myovant Sciences Ltd 34.56%$ 34.559 millions
Assertio Holdings inc 34.31%$ 34.312 millions
Adm Tronics Unlimited Inc 33.86%$ 33.856 millions
Zai Lab Limited33.49%$ 33.494 millions
Natera Inc 33.22%$ 33.217 millions
Electrocore Inc 32.88%$ 32.877 millions
Eiger Biopharmaceuticals Inc 32.41%$ 32.412 millions
Palvella Therapeutics Inc 32.36%$ 32.364 millions
Lineage Cell Therapeutics Inc 32.07%$ 32.070 millions
Inari Medical Inc 31.94%$ 31.938 millions
Biotricity Inc 31.76%$ 31.764 millions
Esperion Therapeutics Inc 31.72%$ 31.723 millions
Establishment Labs Holdings Inc 31.70%$ 31.702 millions
Pacira Biosciences inc 31.12%$ 31.118 millions
Neurocrine Biosciences Inc 31.05%$ 31.047 millions
Skinhealth Systems Inc 30.29%$ 30.295 millions
Therapeutic Solutions International Inc 30.11%$ 30.109 millions
Butterfly Network Inc 29.87%$ 29.875 millions
Medpace Holdings Inc 29.83%$ 29.833 millions


About Aerie Pharmaceuticals Inc Revenue Growth Rates (AERI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Aerie Pharmaceuticals Inc (CIK 1337553).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001337553-22-000041
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Aerie Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.